AMGN Amgen Inc

By Nikki Houston

Bayer AG and Onyx Pharmaceuticals Inc. said Friday a Phase III trial of Nexavar and capecitabine to treat advanced breast cancer failed to meet its primary endpoint.

"We are disappointed that the trial did not show an improvement in progression-free survival in patients with advanced breast cancer," said Joerg Moeller, Bayer HealthCare's Head of Global Development.

The result won't affect the drug's approved treatments for other diseases, he added.

Nexavar, also known as sorafenib, is an oral drug developed and marketed by Bayer HealthCare and Onyx Pharmaceuticals. Onyx Pharmaceuticals is a subsidiary of Amgen Inc.

Write to Nikki Houston at nikki.houston@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires